Related Experiment Videos
[Does chronic therapy of hypertension with acebutolol or hydrochlorothiazide effect coronary risk factors?]
M Witkowska1, G Kübler, E Kopel
1Katedry i Kliniki Kardiologii A.M. We Wrocławiu.
Insights
Neither acebutolol nor hydrochlorothiazide significantly altered key biochemical risk factors in patients with mild to moderate hypertension. This study investigated effects on plasma lipids, lipoproteins, fibrinogen, and fibrinolysis time.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Context:
- Hypertension is a prevalent cardiovascular condition requiring effective management.
- Antihypertensive medications can potentially influence metabolic parameters.
- Understanding the metabolic effects of common antihypertensives is crucial for patient care.
Purpose:
- To investigate the effects of acebutolol and hydrochlorothiazide on plasma lipids, lipoproteins, fibrinogen, and fibrinolysis time in hypertensive patients.
- To assess whether these commonly prescribed drugs induce significant alterations in these biochemical risk factors.
Summary:
- This study examined 78 patients with mild or moderate hypertension, with 42 receiving acebutolol for 18 months and 36 receiving hydrochlorothiazide for 24 months.
- Results indicated that neither acebutolol nor hydrochlorothiazide caused significant changes in the measured biochemical risk factors.
- The study also discussed potential reasons for conflicting findings in existing literature regarding metabolic disturbances from antihypertensive therapies.
Impact:
- Provides evidence that acebutolol and hydrochlorothiazide may not adversely affect key lipid and coagulation parameters in hypertensive patients.
- Contributes to the understanding of the metabolic safety profile of these antihypertensive agents.
- Informs clinical decision-making regarding the choice of antihypertensive medication, particularly concerning metabolic side effects.
Abstract:
In 78 patients with mild or moderate hypertension, effect of acebutolol and hydrochlorothiazide on plasma lipids, lipoproteins, fibrinogen and plasma fibrinolysis time were investigated. 42 patients were treated with acebutolol for 18 months and 36 with hydrochlorothiazide for 24 months. It was shown that neither acebutolol nor hydrochlorothiazide induced significant alterations in investigated biochemical risk factors. The possible causes of controversy encountered in literature and analysis of factors which may influence the character and severity of metabolic disorders resulting from antihypertensive therapy were discussed.